

REMARKS

In the Office Action under reply, claims 7-9, 12-16, and 26-30 are pending. Applicants note with appreciation that Claims 7-9, 12-16, and 27-30 are allowed. Claim 26 is rejected as follows:

1. Under 35 U.S.C. §102(b) as anticipated by Shao, Chemical Abstracts 94:174809;
2. Under 35 U.S.C. §103(a) as being unpatentable over U.S. 3,907,803.

Although not necessarily agreeing with the Examiner's rejections, Applicants have canceled Claim 26, reserving the right to present claim 26 in a continuing application. Thus, all claims that remain pending in the application have been allowed.

CONCLUSION

A Notice of Allowance is requested, and a prompt mailing thereof would be much appreciated. Should the Examiner have any questions, she is invited to contact the undersigned attorney at (650) 384-8755.

Respectfully submitted,

Date: June 1, 2007

By: 

J. Elin Hartrum
Reg. No. 43,663

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
Tel: (650) 384-8755
Fax: (650) 475-0359